Shijiazhuang No.4 Pharmaceutical Co., Ltd.(SJZ No.4 Pharmaceutical), founded in 1948, is a large-scale high-tech pharmaceutical enterprise integrating R&D, production, and global sales. As a listed company on the Hong Kong Main Board, it has firmly established itself as a leader in China’s pharmaceutical industry, ranking among the Top 100 Pharmaceutical Enterprises and honored as one of China’s Excellent Export-Oriented Brands in the chemical pharmaceutical preparation industry, boasting a high reputation in both domestic and international markets.

Export business has always been a core development pillar of SJZ No.4 Pharmaceutical, with its products reaching more than 100 countries and regions across five continents, including Africa, Southeast Asia, Europe and Latin America. The company has maintained a double-digit annual growth rate in export volume for years, ranking the forefront in the domestic pharmaceutical export industry, especially in the large-volume infusion sector, where it has become a leading exporter in China. Its export product portfolio is increasingly diversified, initially focusing on high-quality infusion solutions and now expanding to oral preparations, small-volume injections, APIs and other categories. Its specialty API caffeine, a core export product, is highly recognized globally for its high purity and traceability, with the company being one of the world’s major caffeine suppliers, whose products are sold to over 60 countries and regions.

To ensure the international competitiveness of its export products, SJZ No.4 Pharmaceutical has always adhered to strict quality control and international certification standards. The company has built modern production workshops and automated logistics centers in accordance with EU GMP standards, and its production lines for infusion solutions and other preparations have realized full automation and informatization, reaching the international advanced level. Up to now, the company has obtained 435 product registration certificates in 19 countries including the United Arab Emirates and Costa Rica, and has passed official audits and quality certifications of more than 10 countries such as the Philippines and Peru. In 2025, its caffeine API successfully obtained the EU CEP certification, and its subsidiary Guangxiang Pharmaceutical obtained the carbon footprint report certification in 2024, laying a solid foundation for the company’s products to enter the high-standard international markets such as Europe. The company’s commitment to green production and low-carbon development has also become a key advantage in its international cooperation, winning wide recognition from global partners.

SJZ No.4 Pharmaceutical has formed a complete industrial chain layout from specialty APIs and new preparations to pharmaceutical packaging materials R&D, production and application, with its subsidiary Jiangsu Bosheng Medical New Materials focusing on pharmaceutical packaging R&D, and Hebei Guangxiang Pharmaceutical being an important base for API production. This integrated industrial chain not only ensures the stability of the company’s raw material supply and product quality, but also reduces production costs, enhancing the cost advantage of its export products.

Looking forward, SJZ No.4 Pharmaceutical will continue to adhere to the dual-wheel drive of innovation and international cooperation, increase R&D investment in high-end preparations and innovative drugs, further expand its international certification scope and market coverage, and strive to realize the leap from “scale export” to “value export”. With high-quality products and professional services, the company is committed to becoming a world-renowned pharmaceutical enterprise, making more high-quality Chinese pharmaceutical products go global, and contributing to the global medical and health cause.